• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Understand Companion Diagnostics in Personalized Medicine and Cancer Therapy

Posted on: Tuesday, 4 March 2008, 09:01 CST

Research and Markets (http://www.researchandmarkets.com/reports/c84814) has announced the addition of "Companion Diagnostics in Personalized Medicine and Cancer Therapy" to their offering.

A near-term market opportunity for cancer companion diagnostic tests exists in drug selection for cancer therapy. Co-development of molecular diagnostics and targeted therapeutics has already been proven to be a successful strategy in the development of novel anti-cancer drugs. Adoption of biomarker development in clinical research provides great opportunities to identify patient subpopulations with differential drug responses and to uncover the underlying mechanisms. These data could help to explain if clinical trials of new drugs are adequate, and offer the possibility of creating a clear prescription path based on predictive biomarkers.

The purpose of this report is to describe the specific segment of the diagnostics market that develops new technology platforms for evaluating the metabolism of therapeutic agents, or for evaluating which therapeutic regimes are most effective for a particular type of disease. The term companion diagnostic means that the particular diagnostic test under evaluation is specifically linked to a known therapeutic drug. This linkage could be important in the therapeutic application and clinical outcome of a drug (personalized medicine), or an important component of the drug development process. This report focuses on the former linkage, i.e., the use of companion diagnostic tests in personalized medicine.

Companies Mentioned:

20/20 GeneSystems

Abbott Diagnostics

Affymetrix

Agendia BV

Agensys

Almac Group

AMDL

Arcturus Bioscience

Aureon Biosciences

Beckman Coulter

Biocode S.A.

BioCurex

Biomarker Technologies

Biomedical Diagnostics

Biomerica

bioMérieux

Biomira

BioModa

Bruker Daltonics

Byk Gulden

Cangen Biotechnologies

Caprion Proteomics

Celera Diagnostics

Cepheid

Claros Diagnostics

Clinical Data: PGxHealth and Cogenics

Ciphergen Biosystems

Clarient

Correlogic Systems

Cytogen

Cytyc Corporation

Dako

DiaDexus LLC

Digene Corporation

DiagnoCure

Diagnostic Systems Laboratories

DRG International

DxS

EDP Biotech

Epigenomics

Exact Sciences Corporation

Exagen Diagnostics

Gene Logic

Genesis Genomics

Genomic Health

Gen-Probe

Health Discovery Corporation

Ikonisys

Immunicon

Immunomedics

Incyte Pharmaceuticals

InterGenetics

Ipsogen

LabCorp

Matritech

Miraculins

Mitsubishi Kagaku Medical

Molecular Diagnostics (CytoCore)

Monogram Biosciences

Myriad Genetics

NimbleGen Systems

Northwest Biotherapeutics

Oncotech

Orion Genomics

Oxford Genome Sciences

Panacea Pharmaceuticals

Perlegen Sciences

Polymedco

Power3 Medical Products

Prometheus

Proteome Systems

Qiagen

Sanko Junyaku

SensiGen

SuperArray Bioscience

Third Wave Technologies

Tosoh Medics

TrimGen

TriPath Imaging

Upstream Biosciences

Ventana Medical Systems

Veridex

For more information, visit http://www.researchandmarkets.com/reports/c84814

Source: Business Wire

More News in this Category